+

WO1996015662A1 - Augmentation de la croissance de mollusques et de la production par ceux-ci - Google Patents

Augmentation de la croissance de mollusques et de la production par ceux-ci Download PDF

Info

Publication number
WO1996015662A1
WO1996015662A1 PCT/US1995/014685 US9514685W WO9615662A1 WO 1996015662 A1 WO1996015662 A1 WO 1996015662A1 US 9514685 W US9514685 W US 9514685W WO 9615662 A1 WO9615662 A1 WO 9615662A1
Authority
WO
WIPO (PCT)
Prior art keywords
mollusk
pinctada
enhancing agent
acceptor
growth
Prior art date
Application number
PCT/US1995/014685
Other languages
English (en)
Inventor
Kennedy T. PAYNTER, Jr.
Francis R. Thibodeau
Original Assignee
Paynter Kennedy T Jr
Thibodeau Francis R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paynter Kennedy T Jr, Thibodeau Francis R filed Critical Paynter Kennedy T Jr
Priority to JP51693996A priority Critical patent/JP2002502229A/ja
Priority to EP19950940687 priority patent/EP0792098A4/fr
Priority to AU42354/96A priority patent/AU713205B2/en
Priority to NZ297240A priority patent/NZ297240A/en
Publication of WO1996015662A1 publication Critical patent/WO1996015662A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K61/00—Culture of aquatic animals
    • A01K61/50—Culture of aquatic animals of shellfish
    • A01K61/54—Culture of aquatic animals of shellfish of bivalves, e.g. oysters or mussels
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81—Aquaculture, e.g. of fish

Definitions

  • the present invention generally relates to methods of enhancing the growth of pearl-producing mollusks through the exposure of the mollusks to growth enhancing agents. Also provided are transgenic mollusks capable of expression of exogenous growth enhancing agents, and methods of culturing pearls.
  • the pearl has long been considered a prized jewel valued for both its lustre and brilliance.
  • the pearl is a product of animal origin, being produced by mollusks.
  • a pearl is generally formed when a foreign body becomes embedded in the tissue of a mollusk. Unable to dislodge the foreign body, the mollusk coats it with a calcium carbonate composition which is secreted from its epithelial, or "mantle” tissues.
  • J . Taburiaux, Pearls Their Origin Treatment and Identification , (D. Ceriog-Hughes, Trans., Chilton Book Co., 1986). This secreted material is termed the "nacre.” After a prolonged period, the foreign body is encased in the nacre and has become what is commonly known as a pearl.
  • pearl oysters Modern commercial pearl culturing is practiced using several species of pearl oysters and other mollusks, including abalone, clams and mussels.
  • the pearl oysters are collected from the wild as adults, caught in the wild as juveniles, or "spat", in spat collectors, or can be produced in hatcheries by spawning broodstocks. The oysters are then raised for use in the production of pearls.
  • spat or juvenile oysters also described as pre-adult oysters, require culturing of at least one year before they reach adult size and are large enough to be used for pearl production.
  • a foreign body In the typical pearl culturing process, a foreign body, or "nucleus,” is implanted into the gonadal tissue of a mollusk, typically an oyster species. Where "mabe" pearls are being produced, this nucleus is attached directly to the shell of the mollusk, directly contacting the mantle tissue of the acceptor mollusk.
  • the mantle is a fold of epithelial tissue which surrounds the collection of organs and tissue between the shells, or valves, of the oyster. These organs and the mantle are herein referred to collectively as the "body” of the mollusk.
  • the outer portion of this mantle is generally responsible for periostracum formation and nacre production.
  • a small piece of mantle tissue from a separate, or "donor” mollusk is implanted in the mollusk concurrently with the implantation of the nucleus.
  • the mollusk into which the nucleus and, optionally, the donor tissue is implanted is generally termed the "acceptor" shell or mollusk. Without being bound to any theory, it is believed that the donor mantle tissue surrounds the nucleus as the
  • pearl sac and secretes the nacre which forms the pearl, while the acceptor mollusk acts as a nutritive repository for the process. See, Taburiaux, supra.
  • the time from implantation of the nucleus to harvesting of the pearls can take from eighteen months to three years.
  • growth regulating hormones including those of mammalian origin, such as insulin and growth hormone, have been reported to be effective in accelerating the growth rate of post-larval abalone. See, Morse, Aquaculture , 39:263-282 (1984).
  • the present invention provides methods of enhancing the growth rates of pearl-producing mollusks, and also provides mollusks having enhanced growth rates. Increased growth rates lessen the time required for spat to be cultured prior to their use in pearl production. Additionally, an increase in the growth rate of a pearl producing mollusk results in an increase in the rate of nacre production around implanted nuclei, thus reducing the culturing time for the pearl. Such a decrease in culturing time also increases the number of mollusks that can be recultured, further reducing costs. Therefore, the yield of pearl producers is increased through faster preculturing and culturing processes, recycling of pearl mollusks and reduced flaws in the pearls produced. Further, the potential size of the pearls produced is also be increased.
  • One embodiment of the present invention provides a method of enhancing the growth of a pearl producing mollusk.
  • the method comprises introducing into the germline of the mollusk a nucleic acid sequence, which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence whereby the segment is capable of expressing the growth enhancing agent in the mollusk.
  • the present invention also provides a transgenic mollusk wherein the mollusk's germline comprises an exogenous nucleic acid sequence.
  • This exogenous nucleic acid sequence comprises a segment which encodes a growth enhancing agent, and is capable of expressing the growth enhancing agent in the mollusk.
  • the present invention also provides a method of culturing pearls.
  • This method comprises the steps of introducing a nucleus into an acceptor mollusk.
  • the method may comprise the concurrent introduction of mantle tissue from a donor mollusk into the acceptor mollusk.
  • the acceptor mollusk is exposed to an effective amount of a growth enhancing agent and cultured.
  • pearls are harvested from the acceptor mollusk.
  • the acceptor mollusk is exposed to the growth enhancing agent by immersing the acceptor mollusk in a solution comprising the growth enhancing agent at a concentration of from about 1 nM to about 10 mM of the growth enhancing agent, and more preferably, at a concentration of from about 0.1 ⁇ M to about 100 ⁇ M of the growth enhancing agent. Such exposure is generally carried out from about monthly to weekly to about daily.
  • the acceptor mollusk is exposed to the growth enhancing agent by inserting a composition comprising the growth enhancing agent into the interior of the acceptor mollusk. Insertion of the composition comprising the growth enhancing agent is carried out, for example, by injecting the composition into the interior of the mollusk, or by manually placing the composition in the interior of the mollusk.
  • Such compositions optionally comprise the growth enhancing agent free in solution or incorporated in a matrix, such as a controlled release composition whereby a constant low-level release of the growth enhancing agent occurs.
  • the present invention also provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and mantle tissue from a donor mollusk, where the donor mollusk comprises an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby said mantle tissue from said donor is capable of expressing said growth enhancing agent.
  • the acceptor mollusk is then cultured. Following this culturing, pearls are harvested from the acceptor mollusk.
  • the present invention provides a method of culturing pearls comprising the steps of introducing a nucleus into an acceptor mollusk, and optionally comprising concurrently introducing mantle tissue from a donor mollusk into said acceptor mollusk, said acceptor mollusk comprising an exogenous nucleic acid sequence which encodes a growth enhancing agent, said sequence being operably linked to a promoter sequence whereby the acceptor mollusk is capable of expressing the growth enhancing agent; culturing said acceptor mollusk; and harvesting pearls from said acceptor mollusk.
  • the present invention provides a method for culturing pearls comprising exposing a mollusk to an effective amount of a growth enhancing agent prior to the introduction of a nucleus and optionally the donor mantle tissue. Following introduction of the nucleus, and optionally, the mantle tissue from a donor mollusk, into the interior of the acceptor mollusk, the acceptor mollusk is cultured, and pearls are harvested therefrom.
  • the mollusk is a juvenile, larval or embryonic mollusk.
  • the growth enhancing agent is preferably selected from the group consisting of insulins, insulin-like growth factors and growth hormones. More preferably, the growth enhancing agent is porcine, bovine or human growth hormone or insulin. Most preferably, the growth enhancing agent is porcine, bovine or human insulin.
  • preferred promoter sequences are selected from the group consisting of RSV-LTR, actin and metallothionein promoter sequences.
  • the preferred mollusks of the embodiments of the present invention are selected from the group consisting of Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada maculata, Pinctada albina , Pteria penguin , Unionides sp. and Haliotis sp.
  • such mollusks are selected independently from this group.
  • An object of the present invention is to provide methods of enhancing the growth of pearl producing mollusks as well as provide mollusks having such enhanced growth characteristics. These methods and mollusks are useful in the pearl culturing process to reduce processing time and increase size and number yields of pearl producing mollusks.
  • Mollusks which are particularly useful in the present invention include oyster species such as Pteria penguin, Pinctada maxima, Pinctada mar ger it if era, Pinctada martensi fucata, Pinctada radiata, Pinctada vulgaris, Pinctada fucata, Pinctada albina and Pinctada maculata .
  • Other pearl-producing mollusks including abalone, from the Haliotis genus and fresh water mussels of the Unionides genus. See Taburiaux, supra.
  • the term mollusk is used generically to include adult mollusks, as well as juvenile, larval and embryonic forms thereof.
  • Mollusks having enhanced growth characteristics generally show an increase in one or more of the following characteristics compared with mollusks having normal growth characteristics: shell height, shell length, overall weight or tissue mass.
  • An enhanced growth rate for a mollusk is the change in mass, length or height per unit time of about 1-150, 10-100 or 20-50% greater than that of a normal mollusk of similar size and age in a similar environment. For example, a normal oyster exhibiting an increase in shell length of lOmm/month, would have that rate of increase enhanced to from about 10.1 mm/month to about 25 mm/month.
  • mollusks whose growth rate is enhanced also have increased periostracum formation and shell deposition over those mollusks without an enhanced growth rate. Such increased periostracum formation and shell deposition also increase the rate of nacre production which results in an increase in the rate of pearl formation. Additionally, mollusks having an enhanced growth rate, having achieved a larger size, are capable of harboring larger nuclei and/or pearls within their interior.
  • pearls produced by a mollusk whose growth rate is enhanced or within tissue capable of expressing a growth enhancing agent according to the methods of the present invention generally have a diameter of from about 5 % to about 50 % greater than pearls formed by a mollusk whose growth rate is not enhanced, when cultured under similar conditions for a similar time period.
  • a pearl cultured in a nonenhanced growth mollusk is about 10 mm in diameter
  • a pearl cultured in a mollusk having an enhanced growth rate over the same period is from about 10.5 to about 15 mm in diameter.
  • the mollusk having the enhanced growth rate produces a pearl of given diameter in diameter in about 5-30% less time than a mollusk having a normal growth rate.
  • Growth enhancing agents generally include those compounds which when exposed to living organisms, directly or indirectly induce the growth of the organism, thereby increasing the organism's growth rate over and above the natural growth rate of that organism.
  • compounds essential to the existence of the organism i.e. nutrients, oxygen or water, are not included within the definition of growth enhancing agents.
  • growth enhancing agents include growth hormones, growth factors, insulins and insulin-like peptides.
  • growth enhancing agents include those factors which induce the release of natural growth inducers within the mollusk. These endocrinological "triggers" result in increased expression of the mollusk's natural growth inducers, thus resulting in an enhanced growth rate. These triggers of growth related hormones have been described in other vertebrates.
  • Specific growth hormones which are useful in the present invention include fish growth hormones, i.e., rainbow trout (Agellon and Chen, DNA 5:463-471 (1986)), coho salmon (Villasenor, et al, Gene 65:239-246), and catfish (Tang, et al., Mol . Mar. Biol . and Biotech . , 2(4) :198-206) , as well as bovine, porcine and human growth hormones.
  • insulins which are particularly useful in the present invention include mammalian insulins, such as porcine, bovine and human insulin. See, e.g., Plisetskaya, et al., Gen . Comp . Endocrin .
  • Insulin-like peptides such as human and molluscan insulin-like peptides ("MIP") , are also useful as growth enhancing agents in the methods and mollusks of the present invention. See, e.g., Smit, et al., J. Mol . Endocrin . , 11:103-113 (1993), Smit, et al., Mol . Brain Research , 14:7-12 (1992). Also included are analogs or amino acid sequence variants of these agents.
  • MIP molluscan insulin-like peptides
  • the invention provides methods for enhancing the growth rate of a mollusk and a mollusk having an enhanced growth rate.
  • the mollusks are produced and the methods are practiced by introducing into the mollusk an exogenous nucleic acid sequence which comprises a segment which encodes a growth enhancing agent operably linked to a promoter sequence, whereby the mollusk is capable of expressing the growth enhancing agent.
  • a DNA segment is operably linked when placed into a functional relationship with another DNA segment.
  • a promoter or enhancer is operably linked to a coding sequence if it stimulates the transcription of the sequence;
  • DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide.
  • DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase.
  • enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof.
  • exogenous DNA segment is one foreign to the cell, or homologous to the cell, but in a position within the host cell genome in which the element is not ordinarily found.
  • exogenous DNA segments include heterologous nucleic acid sequences derived from species, genera, families and the like, other than the organism into which it is introduced.
  • Exogenous DNA segments also include a homologous coding sequence operably linked to a heterologous promoter sequence, or alternatively, a heterologous coding sequence operably linked to a homologous promoter sequence.
  • Exogenous DNA segments further include a multiple gene copy nucleic acid sequence where such is not present in the native genome. The presence of multiple copies can result in increased production of the growth enhancing agent relative to expression in the native genome.
  • Exogenous DNA segments are expressed to yield exogenous polypeptides.
  • the nucleic acid sequence encoding the growth enhancing agent is selected from the group of nucleic acids which encode growth hormones, insulins and insulin-like peptides.
  • the nucleic acid sequences for a variety of growth hormones have been reported. See, e.g. , Agellon and Chen, DNA 5:463-471 (1986), Villasenor, et al, Gene 65:239-246, and Tang, et al., Mol . Mar. Biol . And Biotech . , 2(4) :198-206.
  • the nucleic acid sequences for insulin related peptides, and specifically for Human and Molluscan Insulin-like Peptide, have also been reported.
  • nucleic acid sequences for various insulins e.g., human, porcine and bovine, have been reported and are also available from GenBank.
  • Other nucleic acids encoding growth enhancing agents of the present invention can be synthesized, or directly cloned from genomic libraries using, for example, PCR methods. See, e.g., Alberts, et al.. Molecular Biology of the Cell (2nd Ed.
  • the nucleic acid sequence encoding the growth enhancing agent can be genomic, cDNA, minigene (i.e., genomic without selected intronic regions not required for expression) or a hybrid of any of these.
  • the desired sequence is coupled to an appropriate promoter sequence.
  • Promoter sequences useful in the present invention include those of prokaryotic or eucaryotic origin. Generally, promoters that are functional in mammalian cells are also functional in lower eucaryotic forms such as fish or mollusks.
  • Preferred promoter sequences are the long terminal repeat sequence of the Avian Rous Sarcoma Virus (RSV-LTR) (see, e.g., Chen, et al., Mol . Marine Biol . and Biotech . , 2(2):88-95 (1993), Dunham, et al., Mol . Marine Biol . and Biotech . , 1(4/5) :380-389 (1992)), the inducible mouse metallothionein-I promoter, as well as the actin, pgk , tk, and dhfr promoters.
  • RSV-LTR Avian Rous Sarcoma Virus
  • the coding sequence is operably linked to additional control sequences, such as an enhancer, a 3' and/or 5' untranslated region, a 3' and/or 5 1 flanking region, an intronic sequence, a signal sequence capable of directing secretion of the growth promoting factor from the cell in which it is expressed, and a polyadenylation site.
  • additional control sequences such as an enhancer, a 3' and/or 5' untranslated region, a 3' and/or 5 1 flanking region, an intronic sequence, a signal sequence capable of directing secretion of the growth promoting factor from the cell in which it is expressed, and a polyadenylation site.
  • Additional regulatory sequences are often obtained from sequences naturally flanking the coding sequence of the growth promoting factor and/or the promoter.
  • the sequence encoding the growth enhancing agent is fused in-frame to a second exogenous protein-coding sequence, such that the growth enhancing agent is expressed as a fusion protein.
  • the presence of all or part of the second exogenous protein can enhance or facilitate the targeting, stability, acceptance and/or processing of the growth enhancing agent within the cells of the mollusk.
  • Nucleic acid sequences are introduced into the germline of a mollusk embryo to generate a transgenic mollusk.
  • a transgenic mollusk is one in which all of the somatic and germline cells (with the possible exception of a few cells subject to somatic mutation) contain at least one copy of an integrated transgene, the transgene having been introduced into the germline of the mollusk or an ancestor of the mollusk at an early embryonic stage.
  • the nucleic acid can be introduced into individual mollusk embryos at the one- cell (i.e., zygote) or two-cell stage. Introducing DNA at the one-cell stage results in a higher probability of germline incorporation. Incorporation at later stages often results in a mosaic mollusk, only some of whose cells have integrated the transgene.
  • nucleic acids encoding growth enhancing agents can be introduced into mollusks using the same procedure as described for introducing such nucleic acids into t-ransgenic fish. See, e.g., Dunham, et al., supra, Chen, et al., supra.
  • the exogenous nucleic acid segment is introduced into the mollusk by electroporation of a fertilized mollusk egg.
  • the presence of an integrated transgene in the genome of a mollusk is confirmed by extracting DNA from a tissue biopsy and analyzing the DNA for the presence of the nucleic acid sequence, e.g., by Southern analysis of DNA using probes specific for the exogenous nucleic acid sequence of the growth enhancing agent. Expression of the transgene is confirmed by Northern analysis of RNA from the biopsy using a similar probe. Alternatively, a protein extract of the biopsy is analyzed by Western blotting, radioimmunoassay or ELISA using an antibody to the growth enhancing factor being expressed as the probe. True transgenic status is established by transmission of the transgene from PI mollusks to FI progeny.
  • the PI mollusks can be bred either with other PI mollusks or with nontransgenic mollusks. Interbreeding of transgenic mollusks can be used to establish a mollusk line that is homozygous for the integrated transgene.
  • the invention provides methods for culturing pearls by enhancing the growth of the mollusks involved in the pearl culturing process.
  • a foreign body, or "nucleus” is introduced or implanted into the gonadal tissue of a mollusk.
  • the mollusk receiving this nucleus is termed the mother or acceptor mollusk.
  • Nuclei include any foreign body around which the mollusk produces a nacre. Such nuclei are generally small rounded objects, such as fragments of shells from other mollusks, metallic spheres, or other similarly shaped objects. The size and shape of such nuclei depends upon the size and shape of the pearl desired.
  • the invention provides custom shaped nuclei for producing pearls of any desired shape.
  • a piece of tissue from the mantle portion of a mollusk is also implanted in the gonadal tissue of the acceptor mollusk along with the nucleus.
  • the mollusk from which this mantle tissue is derived is termed the "donor" mollusk.
  • the mantle tissue is taken from a separate donor mollusk
  • the mantle tissue can be derived from the acceptor mollusk and reimplanted along with the nucleus in the gonadal tissue of that acceptor mollusk.
  • the acceptor mollusk can also be the donor mollusk.
  • the acceptor mollusk and the donor mollusk are the same species, this need not be the case.
  • the implantation of the nucleus and donor mantle tissue is carried out by conventional methods routine in pearl culturing processes.
  • a nucleus can be implanted between the shell and mantle of the acceptor mollusk, e.g. , in the production of mabe pearls. Where this is the case, the implantation of the donor mantle tissue can be omitted.
  • One embodiment of the present invention provides a method for culturing pearls comprising exposing pre-adult mollusks, e.g., juvenile, spat or larval mollusks, to an effective amount of a growth enhancing agent, whereby the growth rate of the mollusk is enhanced.
  • a nucleus and optionally, mantle tissue from a donor mollusk is introduced into the mollusk.
  • the mollusk is then cultured and pearls are harvested therefrom.
  • Whether a mollusk has reached adult size is dependent upon industry standards for a particular pearl producing mollusk, and as a result, varies from species to species. For example, the larger species of Haliotis have a larger adult size than the more typical Pinctada maxima oyster species.
  • the raising of mollusk spat for use in pearl culturing processes can take upwards of 24 months.
  • the present invention expedites the preculturing aspect of pearl culturing by enhancing the growth rate of juvenile or larval mollusks.
  • the exposing of mollusk spat to an effective amount of growth enhancing agent can comprise immersing the spat in a solution comprising growth enhancing agent at a concentration of from about 1 X 10 ⁇ 9 M (InM) to about 1 X 10" 2 M (lOmM) .
  • immersion treatments should preferably comprise immersing the spat in the composition comprising the growth enhancing agent for from about 30 minutes to about 10 hours, and can be carried out as frequently as necessary to achieve the desired results.
  • such treatments are carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the preculturing process.
  • the present invention provides a method of culturing pearls comprising the steps of introducing into an acceptor mollusk, a nucleus and, optionally, mantle tissue from a donor mollusk, and exposing the acceptor mollusk to an effective amount of a growth enhancing agent.
  • the acceptor mollusk is then cultured, and pearls are harvested therefrom.
  • the nucleus is implanted between the oyster shell and the mantle of the acceptor mollusk
  • the implantation of mantle tissue from the donor mollusk can be omitted.
  • the exposing of the acceptor mollusk to the growth enhancing agent may take a variety of forms.
  • the implanted acceptor mollusk to be exposed to the growth enhancing agent is immersed in a solution which comprises an effective amount of the growth enhancing agent.
  • This immersion treatment is carried out in substantially the same fashion as the treatment described for juvenile or larval oysters. Again, these treatments are preferably carried out daily, semi-weekly, weekly, biweekly or monthly during a portion of, or throughout the pearl culturing process. More preferably, the treatments are carried out during the natural growing season of the mollusk.
  • the solution comprising an effective amount of the growth enhancing agent described above is manually introduced between the valves of the implanted acceptor mollusk.
  • the solution comprising the growth enhancing agent as described above is directly injected into the body or pallial space of the mollusk. While these injections are generally carried out on an implanted acceptor mollusk, these injections may be performed prior to implantation.
  • injections can be carried out by a number of methods, i.e., inserting a syringe needle between the opposing valves of the acceptor mollusk (a natural gap exists between valves in some oyster species, i.e., Pinctada maxima) , filing a notch to produce a small hole in the junction of the two valves, or drilling a small hole in a valve so as to allow the injection of growth enhancing agent between the valves.
  • the solution comprising the growth enhancing agent is injected in a volume of from about 0.5 to about 2.0 mL.
  • the injection is into the pallial or extrapallial spaces of the mollusk so as not to penetrate the organs or tissue which comprise the body of the mollusk.
  • the injection treatments are carried out daily, semi-weekly, weekly, biweekly or monthly.
  • Effective amounts of growth enhancing agents in the above described solutions vary with the particular growth enhancing agent used. In general, effective amount is defined as a combination of concentration of growth enhancing agent in the solution to which the mollusk is exposed, the length of the individual exposure treatments and number and frequency of exposure treatments.
  • the growth enhancing agents are usually present in the above described solutions at a concentration of about 1 X 10 "9 M (lnM) to about 1 X 10 "2 M (lOmM) . More preferred are solutions wherein the growth enhancing agent is present in a concentration of from about 1 X 10 "6 M (1 ⁇ M) to about 1 X 10 " 4 M (100 ⁇ M) .
  • the growth enhancing agent is dispersed in seawater or other appropriate saline solutions.
  • the present invention also provides for the insertion of a controlled release composition comprising a growth enhancing agent in the tissue of the implanted acceptor mollusk.
  • Controlled release compositions are generally in the form of a tablet, capsule or liposome such that the composition is retained within the tissue of the mollusk while releasing a constant low level of the growth enhancing agent.
  • These controlled release compositions generally incorporate the growth enhancing agent in a matrix such that the composition can release effective amounts of the growth enhancing agent over a sustained period of time.
  • the growth enhancing agents are contained within beads, capsules, or microcapsules, surrounded by a barrier which degrades slowly over time to sustain a constant, low level release of the growth enhancing agent into the surrounding environment, without producing degradation products harmful to the mollusk.
  • Compositions useful as barriers are generally commercially available and include, for example, those compositions which are generally used in pharmaceutical applications. See Heller et al., Advanced Drug Delivery Rev . 10:163-204 (1993) and Tyrrell et al., Biochim . Biophys . Acta 457:259-302 (1976).
  • the growth enhancing agents can also be adsorbed to a matrix whereby the growth enhancing agent is slowly released from the matrix in the culturing environment.
  • the controlled release compositions are inserted into the body or tissue of the acceptor mollusk.
  • the controlled release composition can be inserted directly into the gonadal tissue of the mollusk so as to create a region of higher concentration of the growth enhancing agent in the immediate area of pearl formation.
  • the slow dissolving nature of these controlled release compositions prevents them from acting as a nucleus for nacre formation.
  • pearls are harvested from the acceptor mollusks by conventional methods. These mollusks can then be reimplanted for repeated pearl culturing, if desired.
  • the modern pearl culturing process generally comprises the implantation or insertion of a nucleus and a piece of mantle tissue into the gonadal tissue of the acceptor mollusk.
  • this process may vary, for example, where mabe pearls are desired.
  • the nucleus and mantle tissue from a donor mollusk are implanted into a transgenic acceptor mollusk.
  • the transgenic acceptor mollusk comprises an exogenous nucleic acid sequence which comprises a segment encoding a growth enhancing agent operably linked to a promoter sequence.
  • the transgenic acceptor mollusk is thereby capable of expressing the growth enhancing agent.
  • the mantle tissue which is implanted into the acceptor mollusk is obtained from a transgenic donor mollusk.
  • the donor mollusk then comprises the exogenous nucleic acid sequence comprising a segment encoding a growth enhancing agent operably linked to a promoter sequence.
  • the implanted cells from the donor mollusk are thus capable of expressing the growth enhancing agent.
  • This particular embodiment is particularly useful where it is desirable to avoid releasing a transgenic mollusk species into the environment. Therefore, this embodiment is readily be practiced on the scale of a commercial pearl culturing operation.
  • either or both the acceptor and donor mollusks can be transgenic, i.e., capable of expressing an exogenous growth enhancing agent.
  • oysters at various stages of development are used. Accordingly, the initial example describes the raising and culturing of oysters from egg cells to adult oysters.
  • Typical broodstock oysters are collected from the wild just prior to the natural spawning season. These oysters are kept in flow through or recirculating seawater at temperatures just below the natural spawning temperature. These are typically from about 25 to about 30°C. When judged to be in spawning condition by visual inspection of the gonads, the temperature is increased by from about 5°C to about 8°C. This temperature increase usually induces spawning.
  • oysters Upon induction of spawning, oysters are identified as male or female and placed in separate vessels accordingly.
  • the oysters When spawning is complete, the oysters are removed from their respective tanks, and the sperm and egg suspensions are collected and mixed. Once fertilized, the eggs are transferred to another tank to begin the larval culture. Fertilized eggs are stocked at a density of from about 20 to about 30 eggs per ml and kept in aerated tanks for 24 to 48 hours, during which time the eggs hatch. The larvae from the eggs are collected on sieves and placed in tanks at a density of about 20 larvae per ml, and fed algae. The feed is typically a mixture of diatoms and Isochrysis galbana , at a density of 20,000 to 30,000 cells/ml in the larval tanks.
  • Metamorphosis may be chemically induced in some species.
  • Juvenile pearl oysters (Pinctada margeritifera) approximately 1 mm in length, were obtained from a commercial source. These juveniles were maintained in closed recirculating aquaria at 28°C, and fed Thallasiosira and Isochrysis . A subset of the juveniles was immersed in seawater containing 10 "6 M insulin while another group was immersed in seawater alone. After one week, the treated group showed 30% greater growth than the untreated group. Continued weekly immersions resulted in continued accelerated growth of the juveniles over that of the untreated group. No mortality was observed in either group.
  • a slow-release insulin capsule such as described by Heller, supra is inserted into the tissue or gonad of a test group of oysters. Concurrently with the insertion of the insulin capsule, a nucleus of 10 mm in diameter and a 25 mm 2 sample of mantle tissue from a donor oyster are inserted into a separate incision in the gonadal tissue of the test oyster. The oysters are closed and returned to normal culture conditions. After culturing for 12 months, the test oysters are opened and their pearls are harvested. Pearls harvested from these test oysters have a larger diameter and a greater dry weight than pearls produced by the control group.
  • Example 4 Injection of the Growth Enhancing Agent Juvenile Pinctada maxima oysters are removed from their culture conditions. An 18-gauge needle is inserted through the dorsal notch into the pallial space of each oyster. One ml of lOO ⁇ M insulin solution is injected into the oyster. The injected oysters are held out of the water for one hour. After treatment, the oysters are returned to their normal culture conditions. The injections are repeated every 14 days during the growing season. After 12 months, the oysters show greater percent growth than the oysters of the control group.
  • the cDNA sequence of human insulin has been described. See, Gen Bank Ace. No. L15440.
  • the cDNA coding sequence including 3• and 5' untranslated regions and a polyadenylation signal is modified by the addition of Sail linkers and ligated to a Rous Sarcoma Virus long terminal repeat (RSV-LTR) promoter/enhancer sequence at the Sail site in a pRSV-2 vector, as described by Gorman et al, Proc. Natl Acad. Sci. (USA) 79:6777-6781 (1982).
  • the cDNA coding sequence is thereby linked to 580 bp of the LTR sequence and 3.7 kb of pRSV flanking sequence.
  • the vector After propagation of the vector, the vector is linearized to provide a transgene suitable for injection.
  • the linearized transgene is electroporated into fertilized eggs from Pinctada maxima obtained from a commercial hatchery or by laboratory spawning and fertilization.
  • the eggs are cultured to spat and juvenile oysters.
  • the presence of the RSV-LTR-Insulin transgene is assayed from a biopsy of the oyster tissue.
  • Chromosomal DNA is extracted and amplified using primers hybridizable to the transgene.
  • the amplification product is detected by gel electrophoresis. Expression of human insulin is detected by Western blotting of a protein extract from the biopsy.
  • transgenic oysters are interbred to generate transgenic progeny, whose transgenic status and expression is assayed using the same methods as described for the founder oysters.
  • Juvenile transgenic oysters which express the human insulin sequence are cultured under the same conditions as a control group of normal oysters of approximately equal size and age. After culturing for 12 months, the transgenic oysters show a higher percent growth than the oysters of the control group.
  • Set 1 comprises the oysters of Example 5 which demonstrate enhanced growth rates relative to the control group.
  • Set 2 comprises "normal" Pinctada maxima oysters, i.e., nontransgenic oysters.
  • the oysters are implanted with a spherical nucleus 10 mm in diameter, and a 25 mm 2 sample of donor mantle tissue.
  • the following sets of acceptor oysters results:
  • the acceptor oysters are cultured in a marine environment for 12 months.
  • the pearls obtained from the oysters of groups 1, 2 and 3 are larger in diameter and have a greater dry weight than those produced by the control group.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Environmental Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

L'invention concerne d'une manière générale des procédés pour améliorer la croissance des mollusques capables de produire des perles, par exposition des mollusques à un agent stimulant la croissance. L'invention concerne également des mollusques transgéniques capables d'exprimer des agents exogènes stimulant la croissance, et des procédés de culture de perles faisant appel à ces procédés et à ces mollusques.
PCT/US1995/014685 1994-11-18 1995-11-06 Augmentation de la croissance de mollusques et de la production par ceux-ci WO1996015662A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP51693996A JP2002502229A (ja) 1994-11-18 1995-11-06 軟体動物における促進された成長および真珠の生産
EP19950940687 EP0792098A4 (fr) 1994-11-18 1995-11-06 Augmentation de la croissance de mollusques et de la production par ceux-ci
AU42354/96A AU713205B2 (en) 1994-11-18 1995-11-06 Enhancing growth and pearl production in mollusks
NZ297240A NZ297240A (en) 1994-11-18 1995-11-06 Method of enhancing the growth of a pearl producing mollusc by introducing a nucleic acid sequence which encodes a growth enhancing agent into the mollusc, a method of culturing pearl is aslo claimed

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34220394A 1994-11-18 1994-11-18
US08/342,203 1994-11-18

Publications (1)

Publication Number Publication Date
WO1996015662A1 true WO1996015662A1 (fr) 1996-05-30

Family

ID=23340806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014685 WO1996015662A1 (fr) 1994-11-18 1995-11-06 Augmentation de la croissance de mollusques et de la production par ceux-ci

Country Status (5)

Country Link
EP (1) EP0792098A4 (fr)
JP (1) JP2002502229A (fr)
AU (1) AU713205B2 (fr)
NZ (1) NZ297240A (fr)
WO (1) WO1996015662A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032260A1 (fr) * 1997-11-17 2000-09-06 Langdon, Susan Jane Noyau et procede de production de demi-perles ou de mabes
EP1163844A1 (fr) * 1999-02-25 2001-12-19 Miki, Keizaburo Mollusque transgenique et son procede de creation
FR2838023A1 (fr) * 2002-04-05 2003-10-10 Robert Wan Holding Procede de realisation de greffons de culture perliere
US8367355B2 (en) 2009-04-14 2013-02-05 Korea Ocean Research And Development Institute Method of quantitative assessment on reproductive effort of black-lip pearl oysters using antibody specific thereto

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104839053B (zh) * 2014-12-30 2018-06-19 绍兴文理学院 一种快速诱导育珠蚌珍珠囊形成并促进珍珠生长的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5076208A (en) * 1990-09-14 1991-12-31 Massachusetts Institute Of Technology Ultrasound-mediated administration of compounds into aquatic animals
NZ279759A (en) * 1994-02-04 1998-06-26 Univ Leland Stanford Junior Transgenic mollusks

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AQUACULTURE, Volume 39, issued 1984, MORSE, "Biochemical and Genetic Engineering for Improved Production of Abalones and Other Valuable Molluscs", pages 263-282. *
AQUATIC SCIENCE AND FISHERIES ABSTRACTS, August 1994, POWERS et al., "Genetic Engineering a Fast Growing Strain of the Red Abalone Haliotis Rufescens", Abstract Number 124-21838; & 3RD INTERNATIONAL MARINE BIOTECHNOLOGY CONFERENCE: PROGRAM ABSTRACTS AND LIST OF PARTICIPANTS, page 70. *
BIOLOGY BULLETIN, Volume 181, issued December 1991, PAYNTER et al., "Biological Activity of Biosynthetic Rainbow Trout Growth Hormone in the Eastern Oyster, Crassostrea Virginica", pages 459-462. *
See also references of EP0792098A4 *
TABURIAUX, "Pearls Their Origin, Treatment and Identification", Published 1985, by CHILTON BOOK COMPANY (RADNOR, PA), pages 141-160. *
TRANSACTIONS OF THE AMERICAN FISHERIES SOCIETY, Volume 116, issued 1987, DUNHAM et al., "Transfer of the Metallothionein-Human Growth Hormone Fusion Gene Into Channel Catfish", pages 87-91. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032260A1 (fr) * 1997-11-17 2000-09-06 Langdon, Susan Jane Noyau et procede de production de demi-perles ou de mabes
EP1032260A4 (fr) * 1997-11-17 2004-09-15 Langdon Susan Jane Noyau et procede de production de demi-perles ou de mabes
EP1163844A1 (fr) * 1999-02-25 2001-12-19 Miki, Keizaburo Mollusque transgenique et son procede de creation
EP1163844A4 (fr) * 1999-02-25 2002-08-21 Miki Keizaburo Mollusque transgenique et son procede de creation
FR2838023A1 (fr) * 2002-04-05 2003-10-10 Robert Wan Holding Procede de realisation de greffons de culture perliere
WO2003084317A1 (fr) * 2002-04-05 2003-10-16 Robert Wan Holding Procede de realisation de greffons de culture perliere
AU2003233856B2 (en) * 2002-04-05 2006-03-16 Robert Wan Holding Method for the production of pearl culture grafts
US8367355B2 (en) 2009-04-14 2013-02-05 Korea Ocean Research And Development Institute Method of quantitative assessment on reproductive effort of black-lip pearl oysters using antibody specific thereto

Also Published As

Publication number Publication date
JP2002502229A (ja) 2002-01-22
EP0792098A1 (fr) 1997-09-03
EP0792098A4 (fr) 2002-11-05
AU713205B2 (en) 1999-11-25
NZ297240A (en) 1999-10-28
AU4235496A (en) 1996-06-17

Similar Documents

Publication Publication Date Title
Devlin et al. Transmission and phenotypic effects of an antifreeze/GH gene construct in coho salmon (Oncorhynchus kisutch)
Carroll et al. Laboratory culture of the aeolid nudibranch Berghia verrucicornis (Mollusca, Opisthobranchia): some aspects of its development and life history
Lim et al. Use of the rotifer, Brachionus calyciflorus Pallas, in freshwater ornamental fish larviculture
KR101797784B1 (ko) 동물에서 모계 유도성 불임
Arimoro Culture of the freshwater rotifer, Brachionus calyciflorus, and its application in fish larviculture technology
US20050149997A1 (en) Sterilization of marine organisms by manipulation of DNA content
CN102046005A (zh) 大量生产大棘多彩沙鳅的方法
US6015713A (en) Transgenic fish and a method of harvesting islet cells therefrom
Giraspy et al. Australia’s first commercial sea cucumber culture and sea ranching project in Hervey Bay, Queensland, Australia
US6476290B1 (en) Transgenic tilapia comprising a humanized insulin gene
US12286638B2 (en) Transgenic barb
AU713205B2 (en) Enhancing growth and pearl production in mollusks
Keesing et al. Large-scale laboratory culture of the crown-of-thorns starfish Acanthaster planci (L.)(Echinodermata: Asteroidea)
YOSHIZAKI Gene transfer in salmonidae: applications to aquaculture
Liu et al. The clam, Xishi tongue Coelomactra antiquata (Spengler), a promising new candidate for aquaculture in China
Kurbanov et al. Maturation of African catfish, Clarias gariepinus, in condition of seasonal climate of Uzbekistan
CN105941223A (zh) 淡水白鲳的养殖方法
CN114375912A (zh) 一种全雄青虾规模化繁育的方法
Asha et al. Influence of salinity on hatching rate, larval and early juvenile rearing of sea cucumber Holothuria scabra Jaeger
KR100692378B1 (ko) 부화자어 먹이로 이용 가능한 남방소모충 및 이것의 배양방법
Dunham et al. Transgenic fish–where we are and where do we go?
US20080070289A1 (en) Process for storing enriched nematodes
JP5688849B2 (ja) トランスジェニック金魚
US20250143273A1 (en) Transgenic angelfish
CN107173267A (zh) 一种中华乌塘鳢的人工育苗方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR JP MX NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 297240

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995940687

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995940687

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995940687

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载